Qiagen Closes $90M Purchase of SABiosciences, Promises 'Quick and Smooth' Integration | GenomeWeb

This article was originally posted on Dec. 14.

Qiagen said this week that it has completed its $90 million, all-cash acquisition of SABiosciences, a privately held developer of disease- and pathway-focused PCR assay panels.

Peer Schatz, CEO of Qiagen, said in a statement that he believes the integration of the 100-employee, Frederick, Md.-based company into its operations will be "a quick and smooth one," citing the "high level of complementarities" between the firms.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.